WO2018020450A3 - Processes for the preparation of eluxadoline - Google Patents

Processes for the preparation of eluxadoline Download PDF

Info

Publication number
WO2018020450A3
WO2018020450A3 PCT/IB2017/054561 IB2017054561W WO2018020450A3 WO 2018020450 A3 WO2018020450 A3 WO 2018020450A3 IB 2017054561 W IB2017054561 W IB 2017054561W WO 2018020450 A3 WO2018020450 A3 WO 2018020450A3
Authority
WO
WIPO (PCT)
Prior art keywords
eluxadoline
preparation
processes
present
provides
Prior art date
Application number
PCT/IB2017/054561
Other languages
French (fr)
Other versions
WO2018020450A2 (en
Inventor
Vishal Sukhadeo MAWALE
Kumodini Kashinath Mahakal
Pravin Raghunath Mahajan
Gurvinder Pal Singh
Purna Chandra Ray
Girij Pal Singh
Lalitkumar Dilipsing RAJPUT
Radhakrishna Bhikaji SHIVDAVKAR
Original Assignee
Lupin Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Limited filed Critical Lupin Limited
Publication of WO2018020450A2 publication Critical patent/WO2018020450A2/en
Publication of WO2018020450A3 publication Critical patent/WO2018020450A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

The present invention provides a process for the preparation of eluxadoline of formula (I). The present invention also provides a process for the preparation of an amorphous form of eluxadoline. The present invention further provides Form L of eluxadoline and a process for its preparation.
PCT/IB2017/054561 2016-07-28 2017-07-27 Process for the preparation of eluxadoline WO2018020450A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201621025919 2016-07-28
IN201621025919 2016-07-28

Publications (2)

Publication Number Publication Date
WO2018020450A2 WO2018020450A2 (en) 2018-02-01
WO2018020450A3 true WO2018020450A3 (en) 2018-03-08

Family

ID=59714079

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2017/054561 WO2018020450A2 (en) 2016-07-28 2017-07-27 Process for the preparation of eluxadoline

Country Status (1)

Country Link
WO (1) WO2018020450A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10314819B2 (en) 2015-07-23 2019-06-11 Teva Pharmaceuticals International Gmbh Solid state forms of Eluxadoline

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005090315A1 (en) * 2004-03-15 2005-09-29 Janssen Pharmaceutica, N. V. Novel compounds as opioid receptor modulators
WO2009009480A2 (en) * 2007-07-09 2009-01-15 Janssen Pharmaceutica N.V. Novel crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy- benzoic acid
WO2017015606A1 (en) * 2015-07-23 2017-01-26 Teva Pharmaceuticals International Gmbh Solid state forms of eluxadoline
WO2017114446A1 (en) * 2015-12-31 2017-07-06 苏州晶云药物科技有限公司 New crystal form of eluxadoline and preparation method thereof
WO2017153471A1 (en) * 2016-03-11 2017-09-14 Euticals S.P.A. New stable solvate crystalline forms of eluxadolina

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005090315A1 (en) * 2004-03-15 2005-09-29 Janssen Pharmaceutica, N. V. Novel compounds as opioid receptor modulators
WO2009009480A2 (en) * 2007-07-09 2009-01-15 Janssen Pharmaceutica N.V. Novel crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy- benzoic acid
WO2017015606A1 (en) * 2015-07-23 2017-01-26 Teva Pharmaceuticals International Gmbh Solid state forms of eluxadoline
WO2017114446A1 (en) * 2015-12-31 2017-07-06 苏州晶云药物科技有限公司 New crystal form of eluxadoline and preparation method thereof
WO2017153471A1 (en) * 2016-03-11 2017-09-14 Euticals S.P.A. New stable solvate crystalline forms of eluxadolina

Also Published As

Publication number Publication date
WO2018020450A2 (en) 2018-02-01

Similar Documents

Publication Publication Date Title
WO2016149710A8 (en) Hiv-1 neutralizing antibodies and uses thereof
WO2017059059A8 (en) Crystalline forms of a hepatitis b antiviral agent
WO2016130920A3 (en) Lrrk2 inhibitors and methods of making and using the same
WO2018029711A3 (en) Process for the preparation of venetoclax
EP3630738A4 (en) Process for the production of ozanimod
WO2015191945A3 (en) Solid state forms of sofosbuvir
EP3694499A4 (en) Novel process for the preparation of lifitegrast
WO2016038542A3 (en) Solid forms of sofosbuvir
WO2016009401A3 (en) Preparation of tedizolid phosphate
WO2017168447A9 (en) A cyclic compounds and process for the preparation thereof
WO2016108206A3 (en) Processes for preparation of idelalisib and intermediates thereof
WO2018069941A3 (en) Polymorphic forms of venetoclax
EP3615205A4 (en) Process for the preparation of deuterated ethanol from d2
WO2016142819A3 (en) Novel process for the preparation of ranolazine
EP3565552A4 (en) An improved process for the preparation of rivaroxaban involving novel intermediate
EP3548457A4 (en) An improved process for the preparation of 2,3,3,3-tetrafluoropropene
WO2015181802A3 (en) Oral pharmaceutical composition of isotretinoin
WO2015111085A3 (en) Processes for the preparation of eltrombopag and pharmaceutically acceptable salts, solvates and intermediates thereof
WO2015111004A3 (en) Improved process for the preparation of chlorophenyl trifluoroethanone
IN2014MU00626A (en)
WO2016125185A3 (en) Process for the preparation of 4-substituted-1-(trifluoromethoxy)benzene compounds
WO2015114657A3 (en) Amorphous form of sitagliptin free base
EP3727377A4 (en) Process for the preparation of pyrimidinyl-4-aminopyrazole compounds
WO2015102024A3 (en) Novel substituted 5 membered heterocyclic compounds and preparation thereof
WO2018020450A3 (en) Processes for the preparation of eluxadoline

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17758290

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17758290

Country of ref document: EP

Kind code of ref document: A2